IGM Biosciences Inc
IGMS1.390USD
-0.070-4.79%
收盤 04/23, 16:00（美東）報價延遲15分鐘
82.91M總市值
虧損本益比TTM
關於 IGM Biosciences Inc 公司
IGM Biosciences, Inc. 是一家臨牀階段的生物技術公司。該公司致力於開發和提供一類新藥，用於治療癌症和自身免疫性和炎症性疾病患者。該公司的臨牀和臨牀前資產管線基於 IgM 抗體，該抗體具有 10 個結合位點，而傳統 IgG 抗體只有兩個結合位點。該公司還專注於創造、開發、製造和商業化針對腫瘤學和免疫學和炎症靶點的 IgM 抗體激動劑。該公司的開發項目包括 Aplitabart、Imvotamab 和 IGM-2644。Aplitabart 是一種靶向死亡受體 5 (DR5) 蛋白的 IgM 抗體，正在多項 I 期聯合試驗中評估其用於治療結直腸癌的效果。Imvotamab 是一種靶向 CD20 和 CD3 蛋白的雙特異性 T 細胞接合 IgM 抗體。IGM-2644 是一種靶向 CD38 和 CD3 蛋白的雙特異性 T 細胞接合 IgM 抗體。
公司簡介
公司代碼IGMS
公司名稱IGM Biosciences Inc
上市日期Sep 18, 2019
成立日期2012
CEODr. Mary Beth Harler, M.D.
員工數量149
證券類型Ordinary Share
年結日Sep 18
公司地址325 E Middlefield Rd
城市MOUNTAIN VIEW
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94043-4003
電話16509657873
網址https://igmbio.com/
公司代碼IGMS
上市日期Sep 18, 2019
成立日期2012
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lisa L. Decker, Ph.D.
Dr. Lisa L. Decker, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
收入明細
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
暫無數據
地區USD
名稱
營收
佔比
United States
2.68M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 4月2日 週三
更新時間: 4月2日 週三
持股股東
股東類型
持股股東
股東統計
佔比
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
持股股東
股東統計
佔比
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
股東類型
股東統計
佔比
Investment Advisor
27.23%
Investment Advisor/Hedge Fund
15.31%
Hedge Fund
13.66%
Individual Investor
5.49%
Corporation
4.18%
Research Firm
3.12%
Bank and Trust
0.04%
Pension Fund
0.02%
Other
30.94%
機構持股
更新時間: 3月3日 週一
更新時間: 3月3日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
247
34.19M
99.42%
-4.51M
2024Q4
261
34.20M
100.37%
-4.65M
2024Q3
262
33.88M
99.73%
-5.05M
2024Q2
269
34.16M
101.16%
-4.19M
2024Q1
277
34.60M
103.20%
-3.37M
2023Q4
277
33.51M
100.77%
-4.17M
2023Q3
286
34.23M
103.22%
-3.29M
2023Q2
291
34.31M
107.60%
+1.63M
2023Q1
295
29.58M
100.36%
-4.78M
2022Q4
307
29.75M
104.43%
-3.74M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
4.10M
11.91%
+1.91K
+0.05%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.50M
10.18%
-369.20K
-9.54%
Dec 31, 2024
Invus Public Equities Advisors, LLC
3.33M
9.68%
--
--
Dec 31, 2024
Redmile Group, LLC
2.95M
8.58%
-120.35K
-3.92%
Dec 31, 2024
Sanofi
1.44M
4.18%
+1.44M
--
Dec 31, 2024
Goldman Sachs & Company, Inc.
965.88K
2.81%
-279.57K
-22.45%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
952.96K
2.77%
+138.07K
+16.94%
Dec 31, 2024
The Vanguard Group, Inc.
896.35K
2.61%
+6.15K
+0.69%
Dec 31, 2024
Fidelity Management & Research Company LLC
473.43K
1.38%
-346.10K
-42.23%
Dec 31, 2024
State Street Global Advisors (US)
459.45K
1.34%
-10.34K
-2.20%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Range Cancer Immunotherapy ETF
0.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.15%
Invesco NASDAQ Future Gen 200 ETF
0.07%
Global X Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
Range Cancer Immunotherapy ETF
佔比0.15%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.15%
Invesco NASDAQ Future Gen 200 ETF
佔比0.07%
Global X Russell 2000 ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據